This section contains news items that were not issued as a press release.
- Friday, 4 November 2011
- AstraZeneca Wins Scrip Award for “Best Partnership Alliance” AstraZeneca has won the prestigious Scrip Award for “Best Partnership Alliance” for the three-way colorectal cancer collaboration between AstraZeneca, Agendia and the Netherlands Cancer Institute in the 7th annual competition, which acknowledges and celebrates the highest achievers in the pharmaceutical industry.
- Tuesday, 1 November 2011
- AstraZeneca Nobel Medicine Initiative Launched in China Nobel Laureate Professor Barry Marshal Lectures at Inaugural Annual Event in Shanghai and Beijing.
- Tuesday, 25 October 2011
- BioPartnering Europe, London, October 2011 AstraZeneca had a high profile at a recent business partnering event in Europe – sowing the seeds for future deals and supporting our externalisation efforts going forward. There were around 500 delegates at the BioPartnering Europe conference which took place in London from October 9-11th.
- Tuesday, 18 October 2011
- AstraZeneca and Forest Laboratories to initiate phase III clinical trials for ceftazidime/avibactam to treat serious Gram-negative bacterial infections AstraZeneca and Forest Laboratories, Inc. announced today that ceftazidime/avibactam (CAZ-AVI) will enter phase III trials to investigate efficacy in treating hospitalised patients with serious Gram-negative bacterial infections including Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI). CAZ-AVI combines a broad-spectrum cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam, formerly NXL104) to overcome antibiotic-resistance and treat the increasing number of infections resistant to existing therapies.
- Thursday, 29 September 2011
- Cancer Research Technology and Cancer Research UK establish lipid metabolism research team CANCER RESEARCH TECHNOLOGY (CRT) – Cancer Research UK’s commercial arm – has established a group of scientists with expertise in lipid metabolism – getting energy from fats and making building blocks for cell growth – to develop targets for potential new cancer drugs.
- Friday, 23 September 2011
- AstraZeneca and the University of Pennsylvania join efforts to combat the global obesity and diabetes epidemics AstraZeneca and the University of Pennsylvania, Institute for Diabetes, Obesity and Metabolism, have entered into a new collaborative research agreement to identify and develop small or large molecules that enhance differentiation of human adipose stem cells (hASCs) into cells with brown adipocyte properties that could potentially improve body weight control as well as help control glucose and lipid metabolism in type 2 diabetes patients.
- Wednesday, 21 September 2011
- World Alzheimer’s Day - September 21 Alzheimer’s disease is a debilitating disease of the brain that destroys brain cells and robs patients of memory, judgment, the ability to speak or think coherently and to recognize familiar objects and loved ones.
- Tuesday, 20 September 2011
- Academia and industry join forces to improve quality of life for cancer patients A new research partnership between York Health Economics Consortium (YHEC), the University of York, and AstraZeneca will seek to improve oncology care by encouraging more extensive patient feedback on their symptoms and well-being during clinical trials.
- Tuesday, 20 September 2011
- AstraZeneca and Nobel Media Bring Nobel Laureate to China AstraZeneca, a global innovation-driven biopharmaceutical company, and Nobel Media AB, the company responsible for managing and developing media rights in connection with the Nobel Prize, officially launched the AstraZeneca Nobel Medicine Initiative in China. The aim of the global Initiative is to increase interest in the Nobel Prize awarded achievements within the fields of Physiology or Medicine among the general public, students and researchers and to explain the benefits of these discoveries.
- Wednesday, 29 June 2011
- AstraZeneca and PTC Therapeutics announce strategic oncology drug discovery collaboration with potential extension to other therapeutic areas AstraZeneca and PTC Therapeutics, Inc. (PTC) today announced that they have entered into an exclusive research collaboration and license agreement for the application of PTC’s proprietary GEMS™ technology (Gene Expression Modulation by Small-molecules) for the discovery and development of potential new therapies for cancer and other diseases for which there is a great unmet medical need.